Search Results

Displaying Results 1801-1825 of 5672 "'MET'"

May 22, 2026, 09:21 ET Une intelligence verte pour un monde meilleur : XCMG met en avant des solutions intelligentes et durables lors de son 8e Festival international des clients

intelligents couvrant l'ensemble de la chaîne, de tous les scénarios et de tout le cycle de vie.En réponse à la tendance « AI+ », le Festival met à l'honneur les pôles dédiés aux technologies autonomes et les systèmes de construction intelligents. Sur le site d'essai, un ensemble de machines électriques

More news about: XCMG


May 22, 2026, 09:00 ET Prestige Consumer Healthcare, Inc. (PBH) Securities Fraud Investigation - Levi & Korsinsky

forward," while CFO Christine Sacco told investors to "anticipate a 57% adjusted gross margin in Q4." The Q4 results revealed those targets were not met, and the supply-chain remediation that management had repeatedly characterized as on track had not been completed.The Company had guided investors

More news about: Levi & Korsinsky, LLP


May 22, 2026, 08:05 ET Lucosky Brookman's Joseph Lucosky Engages with Lawmakers on Capitol Hill as Debate Intensifies Over Nasdaq's Proposed $5 Million Market Cap Delisting Rule

participants, reflecting his role as a legal and strategic "quarterback" in the microcap and emerging growth markets.Throughout the day, Lucosky met with senior policy advisors and legislative staff from multiple offices, including:Staff for Senator Mike Rounds (R-SD), a member

More news about: LUCOSKY BROOKMAN LLP


May 22, 2026, 08:00 ET AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

post-treatment (SVR12) in the intent-to-treat population (ITT). The study met its primary endpoint, with 96.2% of patients in the ITT population achieving SVR12 (p<0.0001). The key secondary endpoint was also met with 100% of patients in the modified ITT-Virologic Failure population achieving

More news about: AbbVie


May 22, 2026, 07:49 ET Eightco Holdings (NASDAQ: ORBS) rapporteert totale activa van ongeveer USD 333 miljoen, waaronder belangen in OpenAI, Beast Industries, meer dan 11.000 ETH en meer dan 283 miljoen WLD-tokens.

Litigation Reform Act van 1995. Alle verklaringen in dit persbericht, met uitzondering van verklaringen over historische feiten, kunnen als toekomstgerichte verklaringen worden beschouwd, met inbegrip van, maar niet beperkt tot, verklaringen met betrekking tot: de verwachtingen van het Bedrijf dat kunstmatige

More news about: Eightco Holdings (NASDAQ: ORBS)


May 22, 2026, 07:18 ET MHP discussed Global Trade challenges with WTO Director-General in Geneva

Ukraine, May 22, 2026 /PRNewswire/ -- On May 12, Mykhailo Bno-Airiian, Vice-President for Global Affairs at MHP, met with Okonjo-Iweala, Director-General of the World Trade Organization (WTO), at the WTO headquarters in Geneva to discuss current challenges in international

More news about: MHP


May 22, 2026, 06:34 ET ZTE publie son rapport 2025 sur le développement durable : L'IA ouvre un nouveau chapitre dans le développement durable

mondiaux de solutions de technologies de l'information et de la communication, a récemment publié son rapport 2025 sur le développement durable, qui met en évidence les dernières réalisations de l'entreprise en matière d'approfondissement des pratiques ESG. C'est la 18e année consécutive que ZTE publie

More news about: ZTE Corporation


May 22, 2026, 04:00 ET WHO Goodwill Ambassador Issues Rallying Cry to Accelerate International Efforts to Eliminate Leprosy: "The Last Mile Starts Now"

Tedros Adhanom Ghebreyesus and other WHO officials, and Japanese government representatives.Separately, Sasakawa also met with WHO Director-General Dr. Tedros Adhanom Ghebreyesus, WHO Regional Directors, and the health ministers of the 16 priority countries for leprosy,

More news about: Sasakawa Leprosy (Hansen's Disease) Initiative


May 22, 2026, 03:09 ET Caliway Announces U.S. FDA IND Clearance for CBL-0302, Its Second Global Pivotal Phase 3 Study of CBL-514

study's design are strongly supported by Caliway's previously completed Phase 2b clinical studies, CBL-0204 and CBL-0205, which successfully met all primary endpoints.Establishing a New Standard in Aesthetic MedicineBy including objective MRI measurements of fat volume

More news about: Caliway Biopharmaceuticals


May 21, 2026, 21:00 ET BAI Capital annonce la première clôture d'un nouveau fonds de 800 millions de dollars, et continue de soutenir les opportunités de croissance et de mondialisation en Asie

profondément reconnaissants de la confiance et du soutien continus de nos investisseurs actuels et nouveaux. Aujourd'hui, l'environnement d'investissement met plus que jamais l'accent sur la validation, la livraison et la discipline. L'objectif principal du nouveau fonds de BAI n'est pas de poursuivre des concepts

More news about: BAI Capital


May 21, 2026, 18:47 ET Tharaldson Ethanol Increases Oil Recovery with New Technology

Ethanol successfully installed and is operating two Prodec 65 Oil Plus centrifuges as a trial project and, after six months of operation, the results met expectations to move forward with a full capital project implementation. "We are partnering with Alfa Laval and their technology and expertise

More news about: Tharaldson Ethanol


May 21, 2026, 18:46 ET AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

tumors and patient populations, including previously presented data in lung, colorectal and gastric cancers and across patients with MET-amplification and increased c-Met expression.Relapsed/refractory multiple myeloma (R/R MM): Data from a Phase 1b study

More news about: AbbVie


May 21, 2026, 17:17 ET Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

community."Key highlights from the presentations at ASCO and EHA include:In the Phase 3 AcceleRET clinical trial, pralsetinib met the primary progression-free survival (PFS) endpoint and had a significantly greater overall response rate and more durable response vs. standard of

More news about: Rigel Pharmaceuticals, Inc.


May 21, 2026, 17:05 ET Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

2025.Separately, at the American Association for Cancer Research (AACR) Annual Meeting, Johnson & Johnson disclosed JNJ‑95437446, an amivantamab-based EGFR/MET ADC that uses CPT113. In the poster, JNJ‑95437446 reported preclinical findings that support its ongoing Phase 1 clinical development (

More news about: Whitehawk Therapeutics, Inc.


May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting

LIBRETTO-432 study of adjuvant selpercatinib in patients with stage IB-IIIA RET fusion-positive NSCLC. Lilly previously announced that selpercatinib met the primary endpoint, demonstrating a highly significant and clinically meaningful improvement in investigator-assessed event free survival. These results

More news about: Eli Lilly and Company


May 21, 2026, 16:54 ET Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout

Both doses of once-daily pozdeutinurad (AR882) met the primary efficacy endpoint of sUA reduction at month 6 vs placebo Pozdeutinurad was overall well tolerated, and the safety profile was consistent with previous studiesSTOCKHOLM,

More news about: Swedish Orphan Biotrauma AB


May 21, 2026, 16:51 ET Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout

Both doses of once-daily pozdeutinurad (AR882) met the primary efficacy endpoint of sUA reduction at month 6 vs placebo Pozdeutinurad was overall well tolerated, and the safety profile was consistent with previous studiesSTOCKHOLM,

More news about: Swedish Orphan Biotrauma AB


May 21, 2026, 16:10 ET Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

trenibotulinumtoxinE in adult subjects with moderate to severe glabellar lines (M21-500 and M21-508). All primary and secondary endpoints of the Phase 3 studies were met, with a rapid onset of action as early as eight hours after administration (the earliest assessment time) and observed efficacy duration for two to three

More news about: AbbVie


May 21, 2026, 16:05 ET Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China

trial of VGX-3100, INOVIO's investigational DNA immunotherapy being developed as a potential treatment for cervical dysplasia. The trial successfully met its predefined primary efficacy endpoint and demonstrated an overall favorable safety and tolerability profile. ApolloBio plans to use the results from

More news about: INOVIO Pharmaceuticals, Inc.


May 21, 2026, 15:45 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX

results from a phase 2/3 study evaluating its drug tovecimig as a biliary tract cancer treatment. Although the press release emphasized that the study "met the key secondary endpoint of [progression-free survival] and showed additional compelling results", the study also missed another key secondary endpoint,

More news about: Pomerantz LLP


May 21, 2026, 15:45 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alstom S.A. - ALSMY; AOMFF

three-year cumulative €1.5 billion free cash flow guidance, and said that its prior medium-term ambition of adjusted EBIT margin of 8-10% would no longer be met by the end of its next fiscal year. Following these disclosures, Alstom's stock price fell sharply, damaging investors.Pomerantz LLP, with

More news about: Pomerantz LLP


May 21, 2026, 15:03 ET Dự án Tân Hội, Giang Môn của SUS ENVIRONMENT tái định hình mạch sinh thái của các đô thị xanh

trên Con đường tơ lụa trên biển cổ đại. Đội ngũ thiết kế đã sử dụng cánh buồm làm hình tượng kiến trúc chủ đạo, với quần thể công trình dài gần 800 mét trông giống như những cánh buồm căng gió. Mặt dựng nhôm kính khúc xạ ánh sáng lấp lánh như những gợn sóng trên mặt nước. Thiết kế này phá vỡ hiệu ứng

More news about: Shanghai SUS Environment Co., Ltd.


May 21, 2026, 14:56 ET Eightco Holdings (NASDAQ : ORBS) annonce un total d'environ 337 millions de dollars en avoirs, dont OpenAI, Beast Industries, plus de 11 000 ETH et plus de 283 millions de tokens WLD

de plus en plus rares.À propos de Eightco Holdings Inc.Eightco Holdings Inc. (NASDAQ : ORBS) est une société cotée en bourse qui met en œuvre une stratégie de trésorerie Worldcoin (WLD) unique en son genre, offrant aux investisseurs une exposition indirecte à trois des tendances déterminantes

More news about: Eightco Holdings (NASDAQ: ORBS)


May 21, 2026, 14:02 ET VINFAST PRÉSENTE SUR LE MARCHE VIETNAMIEN LA NOUVELLE GÉNÉRATION DU VF 8

développé selon la philosophie « Tech Fluid », qui intègre la technologie au langage stylistique du véhicule et à son utilisation au quotidien. Le design met l'accent sur la fluidité et une impression de mouvement, créant l'apparence d'un SUV moderne et dynamique qui reflète un style de vie contemporain.Le

More news about: VinFast


May 21, 2026, 13:19 ET Un rapport de HCLTech met en garde sur le fait que 43 % des initiatives d'IA en entreprise risquent d'échouer car les dirigeants sont soumis à des pressions de plus en plus fortes sur les délais de présentation de résultats

dirigeantes des entreprises à l'heure actuelle.Pour les DSI et les responsables technologiques, ces résultats révèlent à quel point l'expansion de l'IA met en évidence des contraintes cachées au sein des parcs d'applications, des environnements de données et des modèles d'exploitation qui n'ont pas été conçus

More news about: HCLTech


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.